Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Resolution of Vitreomacular Adhesion (VMA) Associated With Neovascular Age Related Macular Degeneration (AMD) With Intravitreal Microplasmin
Authors not listed
University of California, Los Angeles · 2009
Abstract
The purpose of this study is to determine whether microplasmin given by intravitreal injection is effective and safe for the treatment of wet age-related macular degeneration (AMD) in patients who have focal vitreomacular adhesion (VMA)
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-09 MST
Cite this
APA
Anonymous. (2009). Resolution of Vitreomacular Adhesion (VMA) Associated With Neovascular Age Related Macular Degeneration (AMD) With Intravitreal Microplasmin. <em>University of California, Los Angeles</em>. https://clinicaltrials.gov/study/NCT00996684
Vancouver
Anonymous. Resolution of Vitreomacular Adhesion (VMA) Associated With Neovascular Age Related Macular Degeneration (AMD) With Intravitreal Microplasmin. University of California, Los Angeles. 2009.
BibTeX
@misc{anon2009Resolu,
title = {Resolution of Vitreomacular Adhesion (VMA) Associated With Neovascular Age Related Macular Degeneration (AMD) With Intravitreal Microplasmin},
author = {Anonymous},
journal = {University of California, Los Angeles},
year = {2009},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
IRCCS San Raffaele 2011
Open access · US-GOV
Intravitreal Bevacizumab for the Treatment of Patients With Low Vision Due to Neovascular Age-related Macular Degeneration
Springer eBooks 2008
Citation only
Age‐related Macular Degeneration (AMD)
Novartis Pharmaceuticals 2013
Open access · US-GOV
A 12-month, Phase 3b, Randomized, Visual Acuity Assessor-masked, Multicenter Study Assessing the Efficacy and Safety of Ranibizumab 0.5mg in Treat and Extend Regimen Compared to Monthly Regimen, in Patients With Neovascular Age-related Macular Degeneration
Clinical Interventions in Aging 2006
Open access · OA
Ranibizumab in neovascular age-related macular degeneration
Regeneron Pharmaceuticals 2014
Open access · US-GOV
Phase 1 Safety Study With Intravitreal (IVT) REGN2176-3 in Patients Aged 50 Years and Older With Wet AMD
Unity Health Toronto 2014
Open access · US-GOV